Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB
AstraZeneca AB
Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)
1 trial -
Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo
AstraZeneca AB
Active Proliferative Lupus Nephritis
1 trial -
Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection
AstraZeneca AB
COVID-19
1 trial -
Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.
AstraZeneca AB
Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets
AstraZeneca
HR+ / HER2- advanced breast cancer
1 trial -
Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic obstructive pulmonary disease (COPD)
1 trial -
Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Severe Asthma
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic Rhinosinusitis with Nasal Polyposis
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo
AstraZeneca AB
Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus
1 trial -
Tozorakimab, -, SALBUTAMOL, Tozorakimab-placebo
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Tozorakimab, Tozorakimab-placebo
AstraZeneca AB
Severe viral lung infections
1 trial -
Tozorakimab-placebo, Tozorakimab, SALBUTAMOL
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)
1 trial -
Verzenios 150 mg film-coated tablets, EXEMESTANE, IBRANCE 75 mg film-coated tablets, Verzenios 100 mg film-coated tablets, FULVESTRANT, LETROZOLE, Camizestrant, IBRANCE 100 mg film-coated tablets, Saruparib, Verzenios 50 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, ANASTROZOLE
AstraZeneca AB
Advanced Breast Cancer
1 trial -
ZYTIGA 250 mg tablets, Placebo to match (PTM) AZD5305 film-coated tablets, Saruparib, ZYTIGA 500 mg film-coated tablets
AstraZeneca AB
Prostate Cancer
1 trial -
camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G
AstraZeneca AB
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources